Visit our customer abstracts.
Abstract 519
Loibl, S., et al. Phase III study of palbociclib combined with endocrine therapy in patients with hormone-receptor-positive, HER2-negative primary breast cancer and high relapse risk after neoadjuvant chemotherapy: First results from PENELOPE-B
Abstract 558
Lopez-Guerrero, J. A., et al. MamaPred: a new and innovative approach to determine recurrence risk classification in luminal early-stage breast cancer using HTG EdgeSeq Technology
Featured Publication
Cross-platform comparison of immune-related gene expression to assess intra tumor immune response following cancer immunotherapy
READ PUBLICATION
News & Events
HTG Molecular Diagnostics to Announce Q1 2021 Financial Results and Host Conference Call on Thursday, May 13
TUCSON, Ariz. , May 04, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the quarter ended March 31, 2021 after the market close on Thursday,
- Category:
- Press Releases
16th International Virtual Conference on Malignant Lymphoma
June 18 - 22, 2021| Join us at this international congress to learn more about the latest advances in the science regarding malignant lymphoma.
- Category:
- Future Events
2021 ASCO Virtual Scientific Meeting
June 4 - 8, 2021 | Join us at ASCO and learn about breakthrough research being presented by HTG customers.
- Category:
- Future Events
HTG Molecular Diagnostics Reports Preliminary First Quarter 2021 Financial Results
TUCSON, Ariz. , April 05, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported certain preliminary financial results for the first quarter ended March 31, 2021 .
- Category:
- Press Releases
HTG Molecular Diagnostics Reports Full Year 2020 Results
Call scheduled for today, March 25, at 4:30pm ET TUCSON, Ariz. , March 25, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the year ended December 31, 2020
- Category:
- Press Releases
HTG Molecular Diagnostics to Announce Year End 2020 Financial Results and Host Conference Call on Thursday, March 25
TUCSON, Ariz. , March 16, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the year ended December 31, 2020 after the market close on
- Category:
- Press Releases
Careers at HTG
At HTG Molecular Diagnostics, Inc., we are always looking for talented individuals to help us deliver our next-generation sequencing-based products throughout the world.
Featured Positions
New Careers
Resources
Find product information, specifications and gene lists here.
Publications
Read white papers or journal publications and view other scientific content.
Support
Log in to your account to view technical manuals, package inserts, and other information related to your HTG EdgeSeq system or panels.
Page last updated May 11, 2021
Ready to get started?
HTG is focused on delivering exceptional molecular profiling products and services. Contact us to find out how our unique technology can benefit you.